Back to Journals » International Journal of Nanomedicine » Nanomedicine for Cancer Immunotherapy
ISSN: 1178-2013
- View all (8531)
- Volume 20, 2025 (447)
- Volume 19, 2024 (743)
- Volume 18, 2023 (475)
- Volume 17, 2022 (440)
- Volume 16, 2021 (538)
- Volume 15, 2020 (705)
- Volume 14, 2019 (710)
- Volume 13, 2018 (625)
- Volume 12, 2017 (634)
- Volume 11, 2016 (499)
- Volume 10, 2015 (598)
- Volume 9, 2014 (508)
- Volume 8, 2013 (413)
- Volume 7, 2012 (518)
- Volume 6, 2011 (337)
- Volume 5, 2010 (115)
- Volume 4, 2009 (33)
- Volume 3, 2008 (52)
- Volume 2, 2007 (81)
- Volume 1, 2006 (60)
Journal Articles:
- Unveiling the Potential of Nanobiomaterials: Pioneering Insights into Biomedical Engineering (10)
- Nanomedicine for Cancer Immunotherapy (11)
- Surfactants in Nanomedicine: Enhancing Efficacy and Potential Applications (4)
- Plant-based Nanoparticles for Advanced Medical Applications: Current Trends and Future Prospects (13)
- DNA Nanotechnology Direction Towards Biomedical Applications (1)
- Nanoparticle Applications in Brain Disorders: Gene Therapy and Enzyme Replacement Therapy (6)
- Design, Development, and Translational Science of Inhaled Nanomedicines for Pulmonary, Nasal, and Nose-to-Brain Delivery (2)
- WIBE Thematic Series (7)
- Advanced Nanomedicine: Scrutiny on Unresolved Nanomedicine (6)
- Volume 13 - T-NANO 2014 Abstracts (30)
- Volume 10 - Special Issue on diverse applications in Nano-Theranostics (28)
- Volume 10 - Supplement 1 Challenges in biomaterials research (23)
- Volume 9 - Supplement 2 (26)
- Volume 9 - Supplement 1 (12)
- Volume 8 - Supplement 1 Nanoinformatics (8)
Nanomedicine for Cancer Immunotherapy
Cancer Immunotherapy is a therapy used to treat cancer patients that involves or uses components of the immune system, including antibodies (e.g. anti-PD1/PD-L1), vaccines and T cell infusions, which is a revolutionary technology in oncology. Cancer immunotherapy has made great progress in the past decades and it is thought to be an effective strategy for achieving long-term success in cancer treatment. Despite some clinical successes, some issues, including low patient response rates, adverse effects/immune-related toxicities, and acquired immune resistance need to be solved. This Article Collection shows recent progress in cancer immunotherapy by using nanotechnology. We hope this Collection can help researchers to deepen the mechanisms by which tumor cells evade immunity, reveal how nanomedicine can strengthen the anti-tumor immune-response, and discuss how nanomedicine overcomes the challenges and the critical limitations of cancer immunotherapy.

A Targeted Nanotoxin Inhibits Colorectal Cancer Growth Through Local Tumor Pyroptosis and Eosinophil Infiltration and Degranulation
Carrasco-Díaz LM, Gallardo A, Voltà-Durán E, Virgili AC, Páez D, Villaverde A, Vazquez E, Álamo P, Unzueta U, Casanova I, Mangues R, Alba-Castellon L
International Journal of Nanomedicine 2025, 20:2445-2460
Published Date: 26 February 2025

IL-12-Overexpressed Nanoparticles Suppress the Proliferation of Melanoma Through Inducing ICD and Activating DC, CD8+ T, and CD4+ T Cells
Shen HH, Peng JF, Wang RR, Wang PY, Zhang JX, Sun HF, Liang Y, Li YM, Xue JN, Li YJ, Sun GB, Xie SY
International Journal of Nanomedicine 2024, 19:2755-2772
Published Date: 18 March 2024


Emerging Strategies to Overcome Current CAR-T Therapy Dilemmas - Exosomes Derived from CAR-T Cells
Hu D, Yang R, Wang G, Li H, Fan X, Liang G
International Journal of Nanomedicine 2024, 19:2773-2791
Published Date: 18 March 2024

Analysis of Optimal Treatment Starting Time for Photothermal Therapy Through Analysis of Diffusion Behavior of Gold Nanoparticles
Kim D, Kim H
International Journal of Nanomedicine 2024, 19:3167-3186
Published Date: 3 April 2024


The Application of Nanoparticles Targeting Cancer-Associated Fibroblasts
Huang Q, Ge Y, He Y, Wu J, Tong Y, Shang H, Liu X, Ba X, Xia D, Peng E, Chen Z, Tang K
International Journal of Nanomedicine 2024, 19:3333-3365
Published Date: 8 April 2024

Selective Glycopolymer Inhibitors of Galectin-3: Supportive Anti-Cancer Agents Protecting Monocytes and Preserving Interferon-Gamma Function
Filipová M, Tavares MR, Hovorková M, Heine V, Nekvasilová P, Křen V, Etrych T, Chytil P, Bojarová P
International Journal of Nanomedicine 2025, 20:6591-6609
Published Date: 24 May 2025

Emerging Nanotechnology in Preclinical Pancreatic Cancer Immunotherapy: Driving Towards Clinical Applications
Pan X, Han T, Zhao Z, Wang X, Fang X
International Journal of Nanomedicine 2024, 19:6619-6641
Published Date: 2 July 2024


Nanocarrier-Mediated Immunogenic Cell Death for Melanoma Treatment
Wang J, Ma J, Tai Z, Li L, Zhang T, Cheng T, Yu J, Zhu Q, Bao L, Chen Z
International Journal of Nanomedicine 2023, 18:7149-7172
Published Date: 1 December 2023

Delivery of a STING Agonist Using Lipid Nanoparticles Inhibits Pancreatic Cancer Growth
Shaji SG, Patel P, Mamani UF, Guo Y, Koirala S, Lin CY, Alahmari M, Omoscharka E, Cheng K
International Journal of Nanomedicine 2024, 19:8769-8778
Published Date: 27 August 2024

Nanodelivery Optimization of IDO1 Inhibitors in Tumor Immunotherapy: Challenges and Strategies
Jiang K, Wang Q, Chen XL, Wang X, Gu X, Feng S, Wu J, Shang H, Ba X, Zhang Y, Tang K
International Journal of Nanomedicine 2024, 19:8847-8882
Published Date: 28 August 2024

Synergistic Potential of Nanomedicine in Prostate Cancer Immunotherapy: Breakthroughs and Prospects
Jiang Y, Wang C, Zu C, Rong X, Yu Q, Jiang J
International Journal of Nanomedicine 2024, 19:9459-9486
Published Date: 2 October 2024